Skadden is representing UCB S.A. (Belgium), a biopharmaceutical company, in its US$5.6 billion acquisition via a tender offer of Schwarz Pharma AG (Germany), a pharmaceutical company.
Skadden is representing UCB S.A. (Belgium), a biopharmaceutical company, in its US$5.6 billion acquisition via a tender offer of Schwarz Pharma AG (Germany), a pharmaceutical company.